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did not contribute significantly and was thus not 
incorporated.  
Model 2 incorporated the number of ``High Risk nodal 
stations``(0, 1-2 or ≥3), gender and cT4.  
Model 3 comprised esophageal Dmean and Dmax, gender and 
total GTV. 
Model 1 had an AUC of 0.62, which decreased to 0.58 after 
correction for overfitting. Model 2 yielded an AUC of 0.73 
(corrected for overfitting: AUC=0.70) and model 3 had an 
AUC of 0.69 (corrected for overfitting: 0.67). 
In a secondary analysis, the number of nodal stations close to 
the esophagus correlated with esophageal Dmean and Dmax: 
0.53 (p<0.001) and 0.40 (p<0.001), respectively. 
Conclusions: In SCLC patients referred for treatment with 
accelerated concurrent chemo-irradiation, a predictive 
model for esophagitis grade ≥3 using only clinical variables 
(gender, number of nodal stations close to the esophagus and 
cT4-stage) performs at least as well as a model incorporating 
planning parameters. This allows clinicians to directly 
identify high-risk patients. External validation is ongoing.  
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Purpose/Objective: Esophagitis are one of the acute 
treatment related toxicities to definitive radiotherapy for 
NSCLC. Most current researches about the risk factors for 
acute esophagitis are based on 3DCRT. The purpose of this 
study was to estimate the dose-effect relationship between 
esophagitis and clinical and dosimetric parameters in the 
patients with local advanced NSCLC receiving IMRT and 
concomitant chemotherapy (CCT). 
Materials and Methods: Between 2009 and 2013, 117 
patients with stages IIB-IIIB NSCLC enrolled in the multi 
institution clinical trial NARLAL. All patients were treated 
with 2 cycles of induction chemotherapy followed by IMRT 
and CCT (fixed dose of vinorelbine 50 mg three times per 
week). The maximal esophagitis grade was prospectively 
scored using the Common Toxicity Criteria 3.0. Clinical and 
dosimetric variables were analyzed for the correlation with 
grade ≥2 esophagitis though multivariable logistic regression. 
The optimal dose metrics were chosen using Akaike 
Information Criterion (AIC). All models included one dose 
position parameter, one dosimetric parameter, gender, and 
institution. Dose position was defined as the average relative 
position (zero at start of esophagus and one at the end) 
irradiated above a certain dose. The dose variable was either 
maximum dose, mean dose, the physical length of esophagus 
irradiated above a specific dose (Lx), or the relative volume 
of esophagus irradiated above a specified dose (Vx). To 
validate the impact of the fixed dose of vinorelbine, the body 
surface area was also tested within the models. Data are 
those collected July 2014 and will be updated. 
Results: Grade 1 esophagitis was experienced by 50 (43%), 
grade 2 by 30 (26%), and grade 3 by 10 (8%) patients, 
respectively. The dose parameter in the two models with 
lowest AIC was the relative volume irradiated above 40 Gy 
(V40) (OR=2.39 per additional 10% volume, p<0.001) or length 
of esophagus irradiated above 40 Gy (L40) (OR=4.76 per 
additional 5 cm, p<0.001). The dose position parameter for 
these two models were the average position of esophagus 
irradiated above 20 Gy (P20)(OR=0.37 in V40 Model and 0.45 in 
L40 model per 0.1 relative unit, p=0.002 and 0.011), thus 
irradiation of the upper part of esophagus were more toxic 
than the lower part. The gender was highly significant in both 
models (OR=11.99 in V40 model and 12.45 in L40 model, 
p<0.001) with the female gender experiencing more toxicity. 
Body surface area was not significant in a multivariable 
analysis neither together with the gender variable, nor within 
the two genders separately. 
Conclusions: V40 and L40 were the most effective dosimetric 
predictors of grade 2 or greater acute esophagitis in NSCLC 
patients treated with IMRT and CCT. The position of 
irradiation region of the esophagus showed also to be 
significantly correlated with acute esophagitis. The high OR 
for gender could be somewhat confounded by the body 
surface area. However, the analyses did not support a 
confounding effect. 
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Purpose/Objective: Angiotensin converting enzyme inhibitors 
(ACEi) and angiotensin receptor blockers (ARBs) have been 
shown to decrease the incidence of symptomatic radiation 
pneumonitis (RP) in both the pre-clinical and clinical setting. 
Previously reported outcomes, however, have primarily been 
in the setting of conventionally fractionated radiotherapy; 
similar effects have yet to be established in lung stereotactic 
body radiotherapy (SBRT). The purpose of this study was to 
examine the effect of using an ACEi/ARBs during SBRT on the 
incidence of RP. 
Materials and Methods: 321 patients who received LINAC-
based lung SBRT from January 2008 to June 2013 for early 
stage NSCLC or oligometastases of the lung were identified in 
a prospectively maintained institutional database. Patients 
who received previous thoracic radiation therapy and/or lung 
surgery were excluded. Overall survival (OS) was calculated 
by Kaplan-Meier method. Pulmonary toxicity was assessed 
using the Common Terminology Criteria for Adverse Events, 
v4.03. Statistical comparisons utilized univariate and 
multivariate Cox regression to evaluate the impact of patient 
factors as well as dose-volume histogram parameters on the 
incidence of symptomatic, grade 2 or greater, RP. 
Results: Median follow up time was 13.9 months. Median age 
was 74 years (range, 47-90). Median radiation dose was 54 Gy 
(range, 45-60) with the median number of fractions being 3 
(range, 3-12). The median volume of normal lung that 
received 20 Gy (V20) was 5.5% (range, 1-30). 64 patients had 
a centrally located tumor less than 2 cm from the 
bronchopulmonary tree (19.9%). Two year actuarial OS was 
57.1%. 132 patients were using an ACEi/ARBs at the time of 
receiving SBRT (41.1%); 98 patients were using an ACEi 
(30.5%). Overall, 17 patients had symptomatic RP (5.3%). 
There was no difference in the incidence of RP with 
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ACEi/ARBs users vs. non-users (5.3% vs. 5.3%, p = 1.000). On 
univariate analysis, higher V20 (p = 0.00071), centrally 
located tumors (p = 0.00025), and higher baseline FEV1 
percentage (p = 0.03577) were associated with increased 
incidence of RP. On multivariate analysis, both higher V20 (p 
<0.0001) and centrally located tumors (p = 0.0094) were 
associated with increased incidence of RP. There was no 
identifiable relationship between age, gender, ethnicity, BMI, 
KPS, Charlson comorbidity score, smoking status or history, 
chemotherapy prior to or post SBRT, baseline DLCO, and total 
radiation dose or fractionation with the incidence of RP. 
Conclusions: The use of ACEi/ARBs at the time of lung SBRT 
did not demonstrate a significant association with the 
incidence of symptomatic RP despite previously reported 
data suggesting the opposite. Higher V20’s and centrally 
located tumors, however, were associated with increased 
incidence of RP. Given conflicting data of the protective 
effects an ACEi/ARBs may have against RP, a prospective 
evaluation is necessary.  
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Purpose/Objective: To evaluate the role of coregistered 
4DPET/CT for SBRT target delineation in patients with central 
and peripheral lung tumors. 
Materials and Methods: Analysis of internal target volume 
(ITV) delineation of central and peripheral lung lesions 
(classified according to EORTC 2211-081133) in 21 patients 
treated with SBRT. Manual delineation was performed by 4 
observers in 2 sequential contouring phases: first on 
respiratory gated 4DCT with a diagnostic 3DPET/CT available 
aside (CT-ITV) and secondly on coregistered 4DPET/CT 
(PET/CT-ITV). Comparative analysis of volumes and inter-
reader agreement was carried out for both contouring 
sessions.  
Results: Eleven cases of peripheral and 10 central lesions 
were evaluated. In peripheral lesions, CT-ITV was 6.2 cm3 
and PET/CT-ITV 8.6 cm3, with a small but significant average 
volume increase (p<0.05) resembling a mean change in 
hypothetical radius of 2 mm. For both CT-ITVs and PET/CT-
ITVs inter reader agreement was good and unchanged (0.733 
and 0.716; p=0.58). All PET/CT-ITVs stayed within the PTVs 
derived from CT-ITVs.  
In central lesions, average CT-ITVs were 42.1 cm3, PET/CT-
ITVs 44.2 cm3 with statistically not significant volume and 
hypothetical radius changes. However, inter-reader 
agreement improved significantly (0.665 and 0.750; p<0.05). 
Furthermore, 2/10 PET/CT-ITVs exceeded the PTVs derived 
from CT-ITVs by several ml. 
 
 
Conclusions: The addition of coregistered 4D-PET data to 4D-
CT based target volume delineation for SBRT of centrally 
located lung tumors increases the inter-observer agreement 
and may help in avoiding geographic misses. Hence, it may 
improve treatment accuracy and normal tissue sparing. This 
chance should be further evaluated prospectively.  
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Purpose/Objective: The purpose of this study is to analyse 
the radiotherapy (RT) treatment plans collected in the FAST-
Forward trial to ensure consistency of treatment across all 
centres and compliance with trial protocol. 
FAST-Forward is a multicentre phase III trial comparing a 1-
week course of curative whole breast RT against a standard 
3-week schedule in terms of local control and late toxicity in 
patients with early breast cancer.  
Materials and Methods: A comprehensive set of dose 
objectives for the breast PTV and organs at risk were defined 
for the trial and protocol compliance was assessed against 
these. The dose distribution should fulfil the following 
criteria: 
- PTV V95%≥90%  
- PTV V105%≤7%  
- PTV V107%≤2% 
- Dmax≤110% 
- Ipsilateral lung V30%≤17% 
- Heart V25%≤5% and V5%≤30%  
The analysis was based on a full 3D RT data review for a 
minimum of 10 randomly selected plans from each site, and 
the rest were based on evaluation of the plan assessment 
forms, completed by centres for each patient. Evaluation 
structure compliance was also checked for the reviewed 3D 
datasets. 
Results: The main trial closed after recruiting 4110 patients. 
To date, 3200 plans (78% of recruited patients) from 47 
centres have been collected. 2400 of these have been 
analysed, with full 3D RT data reviewed for 600 (25%) of 
